77111-77-4

Basic information

• Product Name: 2-Chloro-9-(tetrahydropyran-2-yl)adenine
• Synonyms: 2-Chloro-9-(tetrahydropyran-2-yl)adenine;2-chloro-9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-amine(WXC06641);2-CHLORO-9-(TETRAHYDRO-2H-PYRAN-2-YL)-9H-PURIN-6-AMINE
• CAS NO: 77111-77-4
• Molecular Formula: C₁₀H₁₂ClN₅O
• Molecular Weight: 253.69
• Mol File: 77111-77-4.mol
• Article Data: 28

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• Solubility: Chloroform, DCM, DMF, Ether
• CAS DataBase Reference: 2-Chloro-9-(tetrahydropyran-2-yl)adenine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Chloro-9-(tetrahydropyran-2-yl)adenine(77111-77-4)
• EPA Substance Registry System: 2-Chloro-9-(tetrahydropyran-2-yl)adenine(77111-77-4)

Safety Data

• Hazardous Substances Data: 77111-77-4(Hazardous Substances Data)

Usage

Uses

2-Chloro-9-(tetrahydropyran-2-yl)adenine is an intermediate in the synthesis of 2,8-Dihydroxyadenine (D450105), a derivative of adenine which accumulates in 2,8-Dihydroxyadenine Urolithiasis.

Upstream product

• 20419-68-5 2,6-dichloro-9-(tetrahydro-2H-pyran-2-yl)-9H-purine 
• 110-87-2 3,4-dihydro-2H-pyran 
• 5451-40-1 2,6-dichloropurine 
• 5451-40-1 2,6-dichloro-7H-purine 
• 5451-40-1 2,6 dichloropurine 

Downstream Products

• 1050495-33-4 2-[(cyclohexylmethyl)oxy]-9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-amine 
• 1189195-43-4 2-chloro-9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-amine 
• 1050497-12-5 2-{[(1S)-1-methylbutyl]oxy}-9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-amine 
• 1293916-30-9 C₂₈H₃₄N₆O₂ 
• 1293917-23-3 C₂₇H₃₂N₆O₂ 
• 1293916-29-6 C₁₇H₂₀IN₅O₂ 
• 1208368-10-8 phenylmethyl 2-{3-[6-amino-2-(butyloxy)-8-(methyloxy)-9H-purin-9-yl]propyl}-1-piperidinecarboxylate 
• 1208368-13-1 phenylmethyl 3-{[6-amino-2-(butyloxy)-8-(methyloxy)-9H-purin-9-yl]methyl}-1-piperidinecarboxylate 
• 1539304-63-6 C₁₉H₂₁N₅O 
• 28128-30-5 2-methoxy-9H-purin-6-amine 
• 1061457-46-2 6-amino-9-[3-(benzylamino)propyl]-2-butoxy-7,9-dihydro-8H-purin-8-one 
• 1061457-47-3 N-[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl]-N-benzylacetamide 
• 1061226-09-2 methyl 4-[[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl](benzyl)amino]-4-oxobutanoate 
• 1050495-36-7 8-bromo-2-[(cyclohexylmethyl)oxy]-9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-amine 

Relevant articles and documents

COMPOUNDS AS INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR

The present invention provides compounds of Formula (I) shown above and their pharmaceutically acceptable salt, solvates, isomers, or prodrugs, as well as pharmaceutical compositions containing these compounds. Also provided by the invention is a method for treating a disorder mediated by macrophage migration inhibitory factor in a subject, comprising administering to the subject in need thereof a compound or a pharmaceutical composition of this invention.

PURINE AND 3-DEAZAPURINE ANALOGUES AS CHOLINE KINASE INHIBITORS

There are provided substituted purine and 3-deazapurine analogues, which modulate the activity of Choline Kinase (ChoK). The compounds of this invention are therefore useful in treating diseases caused by an altered choline metabolism, such as cancer, cell proliferative disorders, infectious diseases of different origin, immune-related disorders and neurodegenerative disorders. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing pharmaceutical compositions comprising these compounds.

Structural requirements for TLR7-selective signaling by 9-(4-piperidinylalkyl)-8-oxoadenine derivatives

We report the synthesis and biological evaluation of a new series of 8-oxoadenines substituted at the 9-position with a 4-piperidinylalkyl moiety. In vitro evaluation of the piperidinyl-substituted oxoadenines 3a-g in human TLR7- or TLR8-transfected HEK293 cells and in human PBMCs indicated that TLR7/8 selectivity/potency and cytokine induction can be modulated by varying the length of the alkyl linker. Oxoadenine 3f containing a 5-carbon linker was found to be the most potent TLR7 agonist and IFNα inducer in the series whereas 3b possessing a 1-carbon linker was the most potent TLR8 agonist.